Directory
>
Douglas Pagan
Douglas Pagan
CFO/COO | Jnana Therapeutics
Boston, Massachusetts, United States
Douglas Pagan
Summary
Douglas Pagan is an accomplished finance and operations executive with a robust background in the pharmaceutical and biotechnology sectors. Currently serving as the CFO and COO at Jnana Therapeutics, he leverages over two decades of experience to drive financial strategy and operational excellence. His career has spanned various leadership roles, including CFO positions at notable companies such as Dicerna Pharmaceuticals and Ziopharm Oncology. Douglas holds an MBA from Columbia Business School and a BSE in Chemical Engineering from Princeton University. His expertise in finance is complemented by a strong foundation in engineering, enabling him to bridge the gap between technical and financial aspects of the business. He is passionate about fostering innovation within the healthcare industry while maintaining a focus on sustainability and ethical practices. Outside of his professional life, Douglas is committed to mentoring the next generation of leaders in finance and operations.
Douglas Pagan
Work Experience
CFO/COO at
Jnana Therapeutics
April 2022 - Present
Chief Financial Officer at
Novo Nordisk Inc.
May 2020 - March 2022
Director at
Ziopharm Oncology
September 2018 - September 2020
Chief Financial Officer at
KSQ Therapeutics, Inc.
April 2019 - May 2020
Chief Financial Officer at
Paratek Pharmaceuticals
December 2014 - April 2019
Vice President, Finance at
Acceleron Pharma
April 2008 - December 2014
Director, Finance at
Biogen
March 2004 - April 2008
Manager, International Treasury at
Bristol Myers Squibb
July 2002 - February 2004
Associate, Investment Banking at
J.P. Morgan
June 2000 - June 2002
Senior Engineer/Marketing Research Associate at
Johnson & Johnson
June 1993 - August 1999
Douglas Pagan
Education
Columbia Business School, Mba
January 1999 - January 2001
Princeton University, Bse
January 1989 - January 1993
Frequently Asked Questions about Douglas Pagan
What is Douglas Pagan email address?
Douglas Pagan's primary email address is *******@alumni.princeton.edu. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Douglas Pagan work for?
Douglas Pagan is a CFO/COO at Jnana Therapeutics, a company specializing in Commercial physical research.
Where Douglas Pagan graduated from?
Douglas Pagan holds a degree in Finance / Accounting from Columbia Business School.
How can I directly contact Douglas Pagan?
To contact Douglas Pagan directly, you can use the email address *******@alumni.princeton.edu. Complete contact information is available upon registration with Muraena.
Who is Douglas Pagan?
Douglas Pagan is an accomplished finance and operations executive with a robust background in the pharmaceutical and biotechnology sectors. Currently serving as the CFO and COO at Jnana Therapeutics, he leverages over two decades of experience to drive financial strategy and operational excellence. His career has spanned various leadership roles, including CFO positions at notable companies such as Dicerna Pharmaceuticals and Ziopharm Oncology. Douglas holds an MBA from Columbia Business School and a BSE in Chemical Engineering from Princeton University. His expertise in finance is complemented by a strong foundation in engineering, enabling him to bridge the gap between technical and financial aspects of the business. He is passionate about fostering innovation within the healthcare industry while maintaining a focus on sustainability and ethical practices. Outside of his professional life, Douglas is committed to mentoring the next generation of leaders in finance and operations.
Douglas`s contact details
*******@alumni.princeton.edu
******@jnanatx.com
Colleagues
Head of R+D and CMO
Vice President, Head of Early Discovery
Vice President and Head of People & Culture
Vice President, Head of Business Development
Chief Development Officer (CDO)
Vice President, Head of Clinical Operations
Vice President of Finance & Operations
Senior Vice President, Head Of Discovery Sciences
VP Nonclinical Development
Chief Business Officer